Ethanolgel sclerotherapy of venous malformations improves health-related quality-of-life in adults and children – results of a prospective study
- 335 Downloads
To assess the treatment-induced changes of health-related quality-of-life (HRQoL) in patients with venous malformations (VM) who underwent ethanol gel sclerotherapy.
The prospective study in children and adults was approved by the local ethics committee. 31 patients (mean age 23.42 years, range 6.6 – 46.5; 26 female, 5 male) with VM were included. Patients’ self-assessed HRQoL was measured before and after treatment using psychometrically validated questionnaires for adults and children. Differences were analysed with a paired t test.
58 sclerotherapy sessions were performed. The Physical Component Summary (PCS) at baseline was 43.69 and increased significantly (p = 0.01122) to 48.95 after treatment. The bodily pain (BP) scale increased significantly from 37.94 to 48.56 (p = 0.00002), the general health (GH) scale increased significantly from 46.69 to 52.17 (p = 0.00609). Baseline Physical Summary Score (PHS) in children increased significantly after treatment (p < 0.00001) from 25.25 to 45.89. The baseline Psychosocial Summary Score (PSS) in children was 51.08 and increased significantly (p = 0.00031) after treatment to 58.84.
Paediatric and adult patients with VM suffer from bodily pain with overall reduced physical functioning. After sclerotherapy, these restrictions are successfully returning to normal levels with a positive effect on mental and psychosocial domains.
• Sclerotherapy in venous malformation patients has an unknown effect on health-related quality-of-life
• Prospective study showed improvements in bodily pain and general health in adults
• Children and adults improved from treatment with ethanol gel
• Sclerotherapy is an appropriate therapy
KeywordsVascular malformation Sclerotherapy Quality of life Children Adults
The scientific guarantor of this publication is WAW. WAW, WU and RMW declare relationships with the following companies: ab medica, Düsseldorf, Germany (lecturing, proctoring). The authors state that this work has not received any funding. WAW has significant statistical expertise. Institutional review board approval from the Ethikkommission an der Universität Regensburg was obtained. Written informed consent was obtained from all subjects (patients) in this study. Methodology: prospective, longitudinal study, performed at one institution.
- 1.Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A et al (2015) Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 136:e203–e214Google Scholar
- 2.Vogel SA, Hess CP, Dowd CF, Hoffman WY, Kane AJ, Rajaii R et al (2013) Early versus later presentations of venous malformations: where and why? Pediatr Dermatol 30:534–540Google Scholar
- 3.Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P et al (2015) Diagnosis and treatment of venous malformations. Consensus document of the International Union of Phlebology (IUP): updated 2013. Int Angiol 34:97–149Google Scholar
- 4.Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45:S5–S67Google Scholar
- 5.Schumacher M, Dupuy P, Bartoli JM, Ernemann U, Herbreteau D, Ghienne C et al (2011) Treatment of venous malformations: first experience with a new sclerosing agent–a multicenter study. Eur J Radiol 80:e366–e372Google Scholar
- 6.Sannier K, Dompmartin A, Théron J, Labbé D, Barrellier MT, Leroyer R et al (2004) A new sclerosing agent in the treatment of venous malformations. study on 23 cases. Interv Neuroradiol 10:113–127Google Scholar
- 7.Saris-Baglama RN, Dewey CJ, Chisholm GB, Plumb E, King J, Rasicot P et al (2011) Quality metric health outcomes scoring software 4.5 – users guide. Quality Metric Inc. LincolnGoogle Scholar
- 8.Ware JE Jr, Kosinski M, Dewey JE (2000) How to score version 2 of the SF-36® Health Survey. QualityMetric Inc, LincolnGoogle Scholar
- 9.Landgraf JM, Abetz L, Ware JE (1996) The CHQ: a user's manual, 1st edn. The Health Institute, BostonGoogle Scholar
- 11.Balakrishnan K, Bauman N, Chun RH, Darrow DH, Grimmer JF, Perkins JA et al (2015) Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations. Otolaryngol Head Neck Surg 152:948–953Google Scholar
- 15.Boetes C, Boll AP, Hartman PH, van Oostrom CG, Rieu PN, de Rooij M et al (1997) Klippel-Trenaunay-type congenital angiodysplasia syndrome; medical and psychological aspects. Ned Tijdschr Geneeskd 141:650–651Google Scholar
- 22.Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR (1997) MAP-R for Windows: Multitrait/multi-item scale analysis software. Health Assessment Lab, BostonGoogle Scholar